Aficamten (Myqorzo) for obstructive hypertrophic cardiomyopathy.
View Full Paper
Ask AI
Bookmark
Share
Discussion
Loading...
Member takes
Overview
Randomized trial evaluates aficamten's effectiveness in improving heart function in hypertrophic cardiomyopathy, suggesting potential benefits for patients.
Key Points
To assess the effectiveness of aficamten in patients with obstructive hypertrophic cardiomyopathy.
Randomized trial design
Evaluation of heart function and biomarkers
Analysis of patient outcomes following aficamten therapy
Aficamten significantly improved heart function as measured by ejection fraction.
Reduction in obstructive symptoms was observed in the treatment group.
Markedly improved biomarkers related to hypertrophic cardiomyopathy were reported.